China CSCO Hails Rising Liver Cancer Innovation Ready To Take On World
China Transforming From Cancer Research Follower To Leader
Executive Summary
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
You may also be interested in...
China Biotechs Race To Get First Global IO Green Light Within Months
Within months, one of the three latest immuno-oncology drugs from Chinese firms Innovent, Junshi and Akeso is likely to be approved, providing new competition to global giants such as BMS and Merck & Co. as they race each other over to the finish line.
Tecentriq Combo A New Weapon As China Tackles HCC
With the country accounting for 50% of global liver cancer cases, China aims the crosshairs with the help of novel therapies.
Pfizer Bets $480m On CStone And Surging China Immuno-Oncology Market
The latest big pharma vote of confidence in both the China market and R&D capabilities comes amid continuing standoffs with the US over a flurry of issues including the coronavirus, national security and trade, but as the pandemic seemingly recedes in China.